Rationale, Design, and Baseline Data of the Insulin Glargine (Lantus) Versus Insulin Detemir (Levemir) Treat-To-Target (L2T3) Study: A Multinational, Randomized Noninferiority Trial of Basal Insulin Initiation in Type 2 Diabetes-Reference-Cited by-同舟云学术

Rationale, Design, and Baseline Data of the Insulin Glargine (Lantus) Versus Insulin Detemir (Levemir) Treat-To-Target (L2T3) Study: A Multinational, Randomized Noninferiority Trial of Basal Insulin Initiation in Type 2 Diabetes

Published:2009-11 Issue:11 Volume:11 Page:739-743
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Swinnen Sanne G.H.A.¹,Snoek Frank J.²,Dain Marie-Paule³,DeVries J. Hans¹,Hoekstra Joost B.L.¹,Holleman Frits¹

Affiliation:

1. Department of Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands.

2. Department of Medical Psychology, VU University Medical Center, Amsterdam, the Netherlands.

3. Global Metabolism, sanofi-aventis, Paris, France.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2009.0044

Reference25 articles.

1. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

2. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

3. Initial Management of Glycemia in Type 2 Diabetes Mellitus

4. The Burden of Treatment Failure in Type 2 Diabetes

5. Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient characteristics and 6‐month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment ( ORBIT );Journal of Diabetes;2020-05-29

2. Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice;Diabetes Spectrum;2019-05-01

3. Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response;Diabetes Therapy;2018-03-09

4. Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI;Nutrition, Metabolism and Cardiovascular Diseases;2014-12

5. Treat‐to‐target trials: uses, interpretation and review of concepts;Diabetes, Obesity and Metabolism;2013-06-14